Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults and adolescents 6 months and older with ...

Analysts predict peak annual sales of around $2.5 billion for Dupixent, which the FDA approved in March last year for eczema – known medically as moderate-to-severe atopic dermatitis – after ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

LEO will also able to offer patients an alternative to the blockbuster Sanofi/Regeneron Pharmaceuticals drug Dupixent. Atopic dermatitis patients now have a new therapeutic option that comes as a ...

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval ... within the general population with moderate AD and 6 adults per 100,000 with severe AD may be eligible for treatment ...

‘The #atopic_dermatitis market is heating up! #Sanofi is gearing up to challenge #Dupixent's dominance. What new treatments are on the horizon?’ Sanofi is also advancing in the AD arena with ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has ...

including atopic dermatitis (AD), in which it is considered the gold standard, says GlobalData, a data and analytics company. “Having Dupixent as the gold standard for AD, Sanofi has set a high ...